Last reviewed · How we verify
NCT05276336
The Effect of Early Radiofrequency Turbinate Reduction on Persistent Allergic Rhinitis
Phase 3 trial testing Radiofrequency turbinate reduction in Allergic Rhinitis in 32 participants. Completed in 1 February 2020.
1 February 2020
Quick facts
| Lead sponsor | Indonesia University |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 1 July 2018 |
| Primary completion | 1 February 2020 |
| Estimated completion | 1 February 2020 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- Radiofrequency turbinate reduction
- Pharmacology treatment — full drug profile →
Conditions studied
- Allergic Rhinitis — all drugs for Allergic Rhinitis →
Sponsor
Indonesia University
Who can join
Adults 18 to 70, any sex, with Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary outcome of this study is to evaluate the effect of radiofrequency turbinate reduction as an initial treatment on clinical improvement (using visual analogue scale based on total nasal symptoms score, peak nasal inspiratory flow, and turbinate size using ImageJ), inflammatory mediators (ELISA from nasal secretions was performed to measure ECP, IL-5, and HSP-70), and remodeling markers (through nasal biopsy followed by immunohistochemistry examination to evaluate MMP-9, TIMP-1, and PAI-1). In this randomized, controlled trial, 32 patients with moderate-severe persistent AR were randomly divided into 2 groups. Intervention group received radiofrequency turbinate reduction followed by intranasal steroid and antihistamine H-1(AH-1), control group received intranasal steroid and AH-1. Both groups were evaluated for clinical improvement in week 4 and 8 after treatment, inflammatory mediators and remodeling markers in week 4 after treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05276336
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Allergic Rhinitis
Currently open trials in the same condition.
- NCT07453615 — Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children · NA · recruiting
- NCT07419230 — Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project · NA · recruiting
- NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
- NCT07455968 — Free Diving Breathing Training in Allergic Rhinitis · NA · active not recruiting
- NCT07115342 — Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis · NA · recruiting
Other Indonesia University trials
Trials by the same sponsor.
- NCT07137130 — Secretome TGF Beta 3 · NA · not yet recruiting
- NCT07420335 — Preoperative Shoulder Exercises and Postoperative Inflammation, Pain, and Function After Modified Radical Mastectomy · NA · not yet recruiting
- NCT07278284 — The Effectiveness of Press Needle Acupuncture on Preoperative Anxiety in Tympanoplasty and Mastoidectomy · NA · recruiting
- NCT07337187 — Effect of Thread-Embedding Acupuncture at EX-B2 on Pain and Quality of Life in Chronic Low Back Pain · NA · not yet recruiting
- NCT07242001 — Laser Acupuncture for Otitis Media With Effusion in Children · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05276336 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Indonesia University
- Last refreshed: 31 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05276336.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing